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Abstract

Author Manuscript

West Virginia (WV) is situated at the epicenter of the opioid epidemic with the highest rates of
overdose deaths and some of the lowest rates of access to life saving evidence-based medication
assisted treatment (MAT) for patients with opioid use disorder (OUD). WV used a modified huband-spoke model to build organizational capacity for facilities to use buprenorphine to treat
patients with OUD and to provide ongoing case consultation. The purpose of this study is to 1)
describe the group-base model of buprenorphine treatment and the model used to build
organizational capacity, 2) to describe the preliminary results of buprenorphine expansion in WV
and 3) to report preliminary data describing and comparing the characteristics of the patients
served across five hubs. A single Coordinating Center uses video conferencing to train hubs and
provide ongoing case consultation, as well as clinical support. Hubs were trained to deliver a
buprenorphine treatment model that is multi-disciplinary and includes group-based medication
management and psychosocial therapy. Five regional hubs independently treat patients and are
leading MAT expansion in their local areas by training and mentoring spokes (n = 13). As a result
of the WV STR funding, 14 health care facilities have started to use buprenorphine, 56 health
professionals were trained and 196 patients with OUD have been treated. There were few
sociodemographic characteristic differences across patients treated at the five hubs, while there
were differences in self-reported alcohol and drug use in the 30 days prior to intake. Additional
research is needed to determine whether the WV modified hub-and-spoke model resulted in
statistically significant improvements in buprenorphine treatment capacity; there is a need to
address MAT stigma and regulatory barriers in order to ensure the long-term sustainability of the
buprenorphine expansion.
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Introduction
Opioid epidemic & treatment capacity in rural areas
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In 2017, there were 47,600 opioid-involved overdose deaths in the United States (U.S.)
(Scholl, Seth, Kariisa, Wilson, & Baldwin, 2018). Drug overdose deaths occur at higher
rates in rural areas (Rossen, Khan, & Warner, 2013); the largest relative rate increases in
drug overdose deaths between 2016 and 2017 were in counties classified as micropolitan
(10,000 to 49,000 inhabitants) (Ingram & Franco, 2014; Scholl et al., 2018). All of the
counties in West Virginia (WV) are classified as Appalachian and 62% are classified as rural
(Appalachian Regional Commission, 2017; Ingram & Franco, 2014). Over the past decade,
WV has had the highest drug overdose mortality rate in the U.S. (Hall et al., 2008; Scholl et
al., 2018). In 2017, the WV opioid-involved overdose death rate was 49.6 per 100,000,
compared to the national average of 14.9 (Scholl et al., 2018). WV also has high rates of
opioid prescribing (Guy et al., 2017), poverty, low education and high unemployment (Meit,
Heffernan, Tanenbaum, & Hoffmann, 2017); which independently contribute to the risk of
illicit drug use and development of substance use disorders (SUD) (Richman, 1977; Saxe et
al., 2001). WV’s ability to effectively respond to the opioid epidemic has been significantly
hampered by known health care shortages (HRSA 2018); specifically, SUD prevention and
treatment services (Jones, Campopiano, Baldwin, & McCance-Katz, 2015).
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WV is estimated to have the highest rate of past year opioid use disorders (OUD) (12.9 per
1000) in the country; in 2012 all nine of WV’s opioid treatment programs (OTPs) were at
least 80% or greater capacity and the maximum WV buprenorphine treatment capacity rate
(7.0 per 1000) does not meet the demand for services (Jones et al., 2015). According to a
Health Resources and Services Administration December 2018 report, nearly half of WV
residents are in areas designated as health professional shortage areas; 120 primary care and
129 mental health care professionals are needed in these areas (HRSA, 2018). There are
only nine methadone treatment programs in WV and in 2007 a legislative moratorium was
passed preventing new methadone programs from opening. Fifty-five percent of WV
counties do not have a provider waivered to prescribe buprenorphine, which is slightly better
than the national average for rural areas. In 2016, 61% of rural counties nationally did not
have a physician who could dispense buprenorphine (Andrilla, Coulthard, & Larson, 2017).
WV has no statewide public transportation infrastructure and some patients drive 3 h or
more each way for weekly buprenorphine treatment. National research confirms the long
distances that rural patients frequently travel to receive treatment for OUD (Rosenblum et
al., 2011). The large burden of OUD in the state is compounded by a lack of accessible
treatment resources, including both specialty addiction care and primary practice-based
addiction care, particularly in the most rural areas.
The purpose of this study was to 1) describe the group-based model of buprenorphine
treatment and the model used to build organizational capacity, 2) to describe the preliminary
results of buprenorphine expansion in WV and 3) to report preliminary data describing and
comparing the characteristics of the patients served across five hubs. There are unique
challenges to delivering MAT in rural areas including not only shortages of health care
facilities offering medications to treat OUD (Dick et al., 2015; Jones, 2018; Sigmon, 2014),
J Subst Abuse Treat. Author manuscript; available in PMC 2021 January 01.
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but shortages of health care facilities (HRSA 2018) and waivered prescribers who are
willing to treat patients with OUD (Andrilla et al., 2017; Andrilla, Moore, Patterson, &
Larson, 2019). It is important to understand whether there are regional/setting differences
across the expansion sites that can be addressed by modified programming. A modified hub
and spoke model with regional hubs delivering buprenorphine treatment in the context of
psychosocial treatment and training local spokes, integrated by a state Coordinating Center,
may be promising to address the unmet need for OUD treatment.
1.2.

State Targeted Response (STR) funding in West Virginia

Author Manuscript

In May of 2017, WV was awarded $5.8 M as part of the Substance Abuse and Mental Health
Services Administration (SAMHSA) State Targeted Response (STR) grant funding. A
portion of these funds were earmarked to support medication assisted treatment (MAT)
expansion for patients with OUD and this effort was led by WVU’s Department of
Behavioral Medicine and Psychiatry; expansion was modelled on their Comprehensive
Opioid Addiction Treatment (COAT) buprenorphine program (Lander, Marshalek, &
Sullivan, 2016; Zheng et al., 2016; Zheng et al., 2017; Zullig, Lander, Tuscano, Hobbs, &
Faulkenberry, 2018). COAT is a structured outpatient buprenorphine treatment program that
includes group-based medication management appointments directly linked with
psychosocial therapy groups that are stepped down in frequency as patients progress toward
recovery. The COAT buprenorphine treatment model was chosen due to its efficacy and the
efficiency of using a group-based approach in treating a large volume of patients with OUD.
While COAT is not the only effective model of buprenorphine treatment, there were
insufficient resources to support implementation and oversight of multiple buprenorphine
treatment models. A modified version of Vermont’s hub and spoke model (Brooklyn &
Sigmon, 2017) was used to implement the COAT buprenorphine treatment model across the
state. Vermont, a similarly rural state, responded to their limited access to MAT for patients
with OUD by creating a hub and spoke model to expand treatment capacity. Over the course
of 5 years, Vermont’s hub and spoke model generated a 64% increase in buprenorphinewaivered physicians and a 50% increase in patients served per waivered physician, as well as
a robust system for transferring patients between hubs and spokes as appropriate for their
treatment needs. In the Vermont Model, buprenorphine treatment is initiated primarily at a
single hub (e.g., opioid treatment program) and the goal is to transfer patients to the spokes
(e.g., primary care practices) once patients are stabilized on buprenorphine (Brooklyn &
Sigmon, 2017). Whereas in WV, the goal was to develop regional hubs that can
independently and comprehensively treat patients with OUD in their local community. The
regional hubs, in turn, would lead MAT expansion in their local areas by training and
mentoring spokes that can independently and comprehensively treat patients with OUD in
their local community. Neither the hubs or the spokes in the WV model are federallycertified opioid treatment programs.
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1.3.

Comprehensive Opioid Addiction Treatment model (COAT)
The COAT program is located on the WVU Morgantown campus in the Chestnut Ridge
Center (CRC), which served as the Coordinating Center for the STR-funded MAT
expansion. One of the hallmarks of the COAT model is its interdisciplinary team; which
includes different clinicians that are waivered to prescribe buprenorphine/naloxone (MD,
J Subst Abuse Treat. Author manuscript; available in PMC 2021 January 01.
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DO, NP or PA), licensed clinical therapists (MSW, LPC, PhD), case mangers (BA/BS) and
medical assistants. Patients are required to sign a treatment agreement at the time of
enrollment to ensure that they understand the program rules. As part of the model, patients
are required to attend 30-minute group-based medication management visits and 60-minute
group-based psychosocial counseling; as well as attend peer-based mutual support group
meetings in the community. COAT utilizes a phased approach such that the frequency of
treatment sessions progressively declines as patients build consecutive days of abstinence
and increased levels of functioning. Abstinence includes alcohol and any illicit drug use
which is confirmed by urine drug screening; it excludes appropriate use of prescribed
buprenorphine. Random pill counts and call-back urine drug screening are used to confirm
medication compliance, detect potential buprenorphine/naloxone diversion, or illicit
substance use.

Author Manuscript
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The treatment groups usually have between 8 and 12 patients and include groups that are
composed of mixed gender, all female, and pregnant women; as well as groups focused on
specific modalities such as mindfulness or yoga. At the medication management group,
patients are required to provide written verification that they attended at least 4 h of mutual
support group meetings for addiction during the previous week. These meetings mostly
consist of traditional 12-step groups such as AA and NA; but also include SMART
Recovery, Celebrate Recovery and MAT-specific support groups. Buprenorphine/naloxone
prescriptions are provided at the end of the treatment group. The quantity written is
sufficient to last until the next medication management appointment which may be weekly,
biweekly, or monthly (Table 1). The combination buprenorphine/naloxone products are used
almost exclusively, including among pregnant patients, to reduce misuse and diversion
(Lowfall & Walsh, 2014). The combination product has been shown to be safe for pregnant
women and their neonates (Jumah et al., 2016; Lund et al., 2013; Nguyen et al., 2018).
Individual appointments with a therapist are scheduled on a monthly basis or more
frequently as necessary.

Author Manuscript

The treatment team meets for 30 min, prior to the consecutive medication management and
therapy groups, to discuss treatment planning and patients’ overall progress in the program.
This is a critical program component that ensures strong communication across the
interdisciplinary team and team agreement on modifications to individual patients’ treatment
plans. The medication management group is facilitated by a provider waivered to prescribe
buprenorphine. The medical assistant obtains patients’ vital signs and urine drug screens
prior to the group; positive urinalysis results are discussed during the group visit. While
some may be concerned about privacy and potential of shaming due to the discussion of
positive urine toxicology results in a group-based setting, the clinical team uses the group
modality to reduce the shame and stigma associated with relapse. The clinical team does not
use stigmatizing language (e.g., “dirty” urine) and emphasizes honesty about drug use as
part of the recovery process. Further, positive urine toxicology results are opportunities for a
broader discussion of stressful events and other triggers that may precede a relapse.
Confirmatory urine toxicology results are usually individually conveyed to patients,
particularly in circumstances where a higher intensity of clinical care may be needed. The
case manager tracks the patient’s days of abstinence and verifies mutual support meeting
attendance. The group facilitator queries patients about their challenges to sustaining
J Subst Abuse Treat. Author manuscript; available in PMC 2021 January 01.
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recovery, discusses any concerns raised during the earlier treatment team meeting and
provides positive reinforcement of abstinence. The group therapy utilizes evidence-based
practices including cognitive behavioral therapy (CBT), 12 step-facilitation and relapse
prevention techniques (Winstanley, Fishman, & Bolon, 2010, chap. 46) and is facilitated by
a licensed therapist. The goals of therapy are to 1) help build a solid, sustainable recovery
program; 2) develop strategies for relapse prevention; 3) promote peer support and a
supportive social network; 4) develop an understanding of the disease of addiction and 5)
discuss how buprenorphine works to support recovery. The COAT leadership promotes the
use of person-first non-pejorative language (e.g., ‘positive’ urine screen versus ‘dirty’ urine
screen) (Wakeman, 2017) and encourages patients to be honest about their relapses, rather
than relying solely on urine drug screens.
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Over the past 15 years the COAT program has grown rapidly with increasing numbers of
patients, physicians, therapists, case managers and trainees from multiple disciplines. In the
18 months prior to the STR award, the COAT’s main treatment site at the Chestnut Ridge
Center (CRC) had 300+ people on the treatment waiting list for an intake assessment. Even
once patients completed an intake assessment, they often had to wait an additional 2–8
weeks to enter treatment due to limited capacity. As of December 2018, over 3000 patients
had been treated in the COAT program over the last 15 years, there are approximately 550
patients currently in active treatment and there is no active waitlist.
1.4.

Hub and spoke selection and training
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Potential hubs were identified from a list of health care facilities that already participated in
the WV Project Extensions for Community Healthcare Outcomes (ECHO) Medication
Assisted Treatment (MAT) training that began in June 2017. Project ECHO is a video-based
hub- and-spoke model of health care education and mentoring that was developed to
increase community-based health care providers’ capacity to deliver complex specialty care
(Arora et al., 2011). The hubs are usually urban academic medical centers and the spokes are
usually rural primary care practices; disease-specific (e.g., addiction, Hepatitis C) Project
ECHO models have been developed. New Mexico saw a dramatic increase in the number of
buprenorphine-waivered prescribers after the implementation of an integrated addictions and
psychiatry Project ECHO (going from 36 to 375) (Komaromy et al., 2016). The WV Project
ECHO program is used to provide ongoing training for the hubs and spokes, as well as
provide ongoing case consultations with the CRC Coordinating Center. The WV Project
ECHO program was developed and implemented through funding and support from the West
Virginia Clinical & Translational Science Institute (WVCTSI), Claude Worthington
Benedum Foundation, WVU School of Medicine, Cabin Creek Health Systems, Anthem
Insurance and the WV Primary Care Association in partnership with Project ECHO®.
Typical WV Project ECHO MAT sessions include didactics on topics ranging from
substance use disorders, myths and facts about MAT, interpreting lab results, stigma,
psychosocial/behavioral treatments and evaluating case severity. Case presentations
routinely occur with time allotted for discussion. In year 2 of the STR funding, the newly
formed hubs are working to develop their own ECHO-based model to provide video-based
supervision and case consultation for their spokes.
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Five hubs were recruited from around the state (see Fig. 1) and the sites were chosen based
on the following criteria: 1) geographic proximity to serve areas with high demand, 2)
having a university affiliation or willingness to train new buprenorphine providers and 3)
expressing active interest in MAT and/or already being actively trained by the CRC
Coordinating Center.
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The current hubs are WVU Department of Behavioral Medicine and Psychiatry’s Lakewood
Clinic (psychiatry, Morgantown), Marshall University’s Recovery Center (psychiatry,
Huntington), Charleston Area Medical Center (psychiatry, Charleston), Harpers Ferry
Family Medicine (primary care, Harpers Ferry) and Cabin Creek Health Center (Federally
Qualified Health Center (FQHC), primary care, Kanawha City) (see Fig. 2). Prescribers at
the hubs and spokes are varied in their training and specialization and include addiction
psychiatry, general psychiatry, internal medicine, primary care, emergency medicine,
obstetrics and gynecology.
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Each hub team, which consisted of a prescriber, therapist and case manager, was initially
trained on-site at CRC on the COAT buprenorphine treatment model. The hub treatment
teams shadowed the COAT program (treatment team meetings, medication management and
therapy groups) twice at the CRC and attended at least two days of training at each visit.
COAT team members then visited each hub twice, shadowing the hub clinic operations and
offering both verbal and written feedback. The hubs participate in bimonthly video
conference calls with the CRC Coordinating Center and they are required to attend twice
monthly 60-minute WV Project ECHO MAT sessions. Hubs and spokes are provided with
written materials detailing policies and procedures of the COAT buprenorphine treatment
model, group therapy content resources, a COAT quick tips booklet and a COAT pocket
guide. The same training structure was used for training the spokes; each spoke trained at
their affiliated hub twice and twice trained at the spoke’s clinic. Hubs can access ongoing
support from the CRC Coordinating Center via e-mail and phone consultation as needed.
Once trained, hubs and spokes can tailor the buprenorphine treatment model to fit the needs
of their clinical organization and their local patients. In Year 2 of the project, each hub has
begun developing 2–3 spokes to train and support in the delivery of MAT services using the
COAT buprenorphine treatment model. In a rural state this innovative means of training and
dissemination of evidence-based treatments is essential to reach as many providers as
possible and to increase the comfort level of providers working with this population.
Training and ongoing consultation is particularly critical for providers without training in
behavioral medicine or addiction treatment (e.g., primary care providers, OB/GYN).

Author Manuscript

2.
2.1.

Methods
Participants, measures & data collection
All patients enrolled in treatment at hubs between January and December 2018, and who
completed the intake forms, were included in the analysis. As the spokes have only recently
begun to treat patients with buprenorphine, these patients (n = 11) were not included in the
analysis. The Government Performance and Results Modernization Act (GPRA) data form
was collected on all new patients within 10 days of being prescribed buprenorphine/
naloxone. The GPRA form collected information on modality of planned services, treatment
J Subst Abuse Treat. Author manuscript; available in PMC 2021 January 01.
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services (medical, case management, education and aftercare), sociodemographic
characteristics of clients served (race, ethnicity, living situation, education, employment),
alcohol and drug use (past 30 day use, route of administration), past month health care
utilization, mental health and social connectedness. All of the hubs received training
sessions in-person and via video conference on how to complete the GPRA data collection
forms. The GPRA form was completed either by the therapist conducting the drug and
alcohol evaluation or by the case manager. GPRAs were securely electronically sent or
mailed to the CRC where data was entered into a REDcap database. GPRA measures were
collected at baseline (within 10 days of buprenorphine initiation) and at 6-, 12-month
follow-up; and at discharge. Given the limited amount of follow-up data available and that
spokes are still being trained to use buprenorphine to treat patients with OUD, only baseline
data from the hubs is reported.

Author Manuscript

2.2.

Data analysis
Stata/MP Version 15.1 was used to run descriptive statistics (StataCorp, 2017). Chi-square,
fisher’s exact and ANOVA were used to compare patient characteristics across the sites.
Statistical significance is defined as a p value ≤ 0.05. The West Virginia University
Institutional Review Board approved this project.

3.
3.1.

Results
Buprenorphine training and expansion

Author Manuscript

As a direct result of the STR funding, 56 health professionals were trained in the COAT
treatment model and this included 19 physicians, 2 nurse practitioners, 1 nurse, 10
therapists, 10 case managers, 3 medical assistants, 10 administrators and 1 scribe. Thirteen
spokes have been identified and nine spokes have initiated treatment. Four providers have
been newly waivered to prescribe buprenorphine; it is anticipated that additional providers
will be waivered as the remaining spokes implement buprenorphine/naloxone treatment
(Table 2).
3.2.

Buprenorphine expansion patient characteristics
A total of 196 patients have been served between January to December 2018. The mean
patient age was 35.0 years old; patients ranged in age from 20 to 72 years old. A little more
than half (53.6%) of the patients were male, the vast majority of the patients were White
(94.9%), 3.6% were Black and 2.0% were American Indian. A fourth (26.5%) of patients
reported having children and 14.4% of the women reported being currently pregnant.

Author Manuscript

More than a third (36.1%) of patients reported injection drug use in the past month and
among those, 49.2% reported sharing syringes or other injection equipment. Forty-three
patients reported injecting heroin; 33 reported injecting methamphetamine and 3 reported
injecting buprenorphine. Regarding functional/emotional difficulties related to their drug/
alcohol use, 38.5% reported that things were extremely stressful because of their alcohol/
drug use and 41.0% reported that their alcohol/drug use has caused them to give up
important activities at either a “considerable” or “extreme” level. A little more than half
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(53.3%) reported that they had considerable or extreme emotional problems because of their
alcohol/drug use.

Author Manuscript

When asked about their health, 50.3% reported that their overall health was “fair” or “poor”.
When asked about their cognitive functioning, 39.4% reported trouble understanding,
concentrating or remembering. The majority of patients reported having mental health
problems, a little less than half (46.4%) reported having been considerably or extremely
bothered by mental health problems in the past month and 31.6% had been prescribed
psychotropic medications in the last 30 days. More specifically; 63.2% reported
experiencing serious depression, 72.0% reported serious anxiety or tension and 4.3%
reported experiencing hallucinations. Few (2.1%) patients reported a history of suicide
attempt(s) and 7.5% reported trouble controlling violent behavior. While 73.9% of patients
reported having family support, 15.2% reported having no one to turn to when they were
having trouble. A third of patients (35.3%) reported having attended a self-help group in the
past month and 11.8% reported attending a religious or faith-based recovery group in the
past month.
3.3.

Patient differences across hubs
There were minimal sociodemographic and clinical differences between the patients served
across the hubs. Morgantown and Charleston, two of the largest cities in the state, had more
patients reporting depression and anxiety symptoms (see Table 2).

Author Manuscript

There were notable statistically significant differences across the sites in respect to patterns
of alcohol and drug use (see Table 3). Patients treated in the Kanawha City site reported
higher mean days of alcohol use (12.2 compared to 8.0 overall). Patients treated at the
Morgantown site reported (73.7%) higher rates of overall illegal drug use (59.2%) and
higher overall alcohol and illegal drug use (24.2% compared to 17.5% overall). Patients
treated at the Charleston site reported significantly higher rates of any prescription opioid
use (75.0% compared to 24.2%), as well as higher rates of benzodiazepine use (43.8%
versus 24.2% overall). Patients treated at the Kanawha City site reported higher rates of
methamphetamine use (64.3%), whereas patients at the Harpers Ferry site infrequently
reported past month methamphetamine use (4.8%). There were significantly higher rates of
cocaine use reported among patients treated at the Huntington site (40.0%) and at the
Harpers Ferry site (30.8% versus 15.8% overall). Overall, 47.4% of patients reported illicit
buprenorphine use where Morgantown had the highest percentage (69.7%).

4.
Author Manuscript

4.1.

Discussion
General discussion
WV’s overdose death rate in 2017 was more than triple the national average and for the past
decade the number of overdose deaths in WV has increased annually (Scholl et al., 2018).
The ability of the state to effectively respond to the opioid epidemic is constrained by not
only a shortage of opioid treatment programs, but also by an overall shortage of health care
professionals (HRSA, 2018). Despite the passage of the Drug Addiction Treatment Act of
2000 (DATA, 2000), which allowed for office-based prescribing of buprenorphine, national
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research has found that few primary care physicians are willing to be trained to prescribe
buprenorphine and even those trained may not treat as many patients as allowed (Walley et
al., 2008). Clinicians working in HRSA-designated health professional shortage areas are
already overwhelmed and treating patients with OUD may be particularly daunting.

Author Manuscript

The WV STR was successful in training five hubs and 56 health professionals to use the
COAT buprenorphine/naloxone treatment model; and the hubs have treated 196 patients with
buprenorphine from January to December 2018. The five hubs serve geographically diverse
regions of the state and are able to serve as local MAT champions by training and mentoring
health clinics (‘spokes’) in their region. The hubs have identified a total of 13 spokes; 8 of
which are beginning to deliver buprenorphine treatment as part of a comprehensive MAT
program that includes psychosocial treatment. The hub and spokes represent different health
care settings including psychiatry (n = 6), primary care (n = 8) and a women’s health clinic
(n = 1). The WV MAT expansion was successful in involving a diversity of health
professionals trained, from a variety the health care settings, because of the strong ongoing
training framework provided by the WV Project ECHO MAT. Further, involvement in the
WV Project ECHO MAT may be associated with the rate of buprenorphine adoption. It is
certainly possible that WV Project ECHO MAT serves not only as a strategy to train
providers to prescribe buprenorphine and treat patients with OUD, but also serves to provide
ongoing mentorship and to build trust between the hubs and spokes.
4.2.

MAT stigma
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There are significant challenges and barriers to continued MAT expansion, which may
threaten long-term sustainability. For example, stigma toward patients with OUD, as in
many states, continues to be problematic in the recruitment of health clinics as potential
spokes. Patients may also encounter stigma when attending mutual support groups (Hadland,
Park, & Bagley, 2018) as required by the COAT buprenorphine treatment model. Many
mutual support groups in WV are abstinence-based and they define any opioid use,
including buprenorphine, to be inconsistent with their philosophy. Patients have reported that
even their family members have stigmatizing views of MAT, perceiving it as drug
substitution. Problems with MAT-related stigma are not unique to WV (Olsen & Sharfstein,
2014); however, rural areas make anonymity difficult and its consequences may be felt more
deeply in Appalachian culture that values familism (Batteau, 1980).
4.3.

Organizational and regulatory barriers

Author Manuscript

To date, only one buprenorphine waivered primary care doctor has discontinued treating
patients; however, it is unknown whether preserver retention will become a larger problem in
the future and whether anything can be done to prevent prescriber attrition. One major
concern raised by the health professionals involved in the MAT expansion is the
sustainability of case manager funding. The case managers, currently supported through the
STR-funding, are a key component to the clinic structure and are desperately needed to
support prescribers working with large numbers of patients. Unfortunately, none of the hubs
are licensed behavioral health centers and therefore they are unable to bill for targeted case
management services once STR-funding ends. Reimbursement for case management
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services is critical to the long-term sustainability of MAT expansion in WV, particularly in
non-psychiatric settings.
The WV Project ECHO MAT provides an excellent mechanism to deliver ongoing clinical
training; however, there is a need for more in-depth training for treating patients with OUD
with high acuity and/or patients with complex co-occurring psychiatric and medical
conditions. Whereas urban areas may be able to simply refer patients to other specialists
(e.g., infectious disease or mental health clinics), in Appalachian rural counties specialty
care is sparse. Therefore hubs and spokes have taken on not only buprenorphine treatment,
but also treating the psychiatric and medical consequences associated with long-term opioid
addiction. Finally and not surprisingly, the logistical challenges commonly found in rural
economically-disadvantaged areas remain, such as transportation to treatment, childcare for
patients, and availability of mutual support groups, especially those supportive of MAT.
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There are WV-specific treatment delivery regulations that further confound the provision of
services. Regulatory requirement 69 CSR 12, which was initiated in June 2017 for office
based opioid treatment (OBOT), stipulates that OBOT settings be licensed by the WV
Department of Health and Human Resources (DHHR) and subject to inspection by the
Office of Health Facility Licensure and Certification (OHFLAC). The regulation outlines
specific requirements including that patients be seen with certain frequency per month, with
specified number if urine drugs screens monthly and required number of psychosocial
interventions, which make it difficult for health care settings that do not have the capacity or
resources to meet these regulatory requirements. These regulations also contribute to lower
retention rates for patients who struggle with transportation or low motivation to participate
in psychosocial treatment. Regulatory barriers have been documented as buprenorphine
adoption barriers in other rural states (DeFlavio, Rolin, Nordstrom, & Kazal, 2015).
4.4.

Limitations

Author Manuscript

Despite the strengths of the current report, there are some limitations which warrant
discussion. First, providers who were trained were not formally tracked as part of the
evaluation nor was a formal implementation study conducted. Second, the GPRA data
collection forms do not include a question to identify patients that transferred from another
MAT program nor a question on illicit buprenorphine use. The hubs were trained to track
illicit buprenorphine in the ‘other’ drug category; however, it is probable that this was
inconsistently captured and it is notable given that 47% of patients did report illicit
buprenorphine use in the 30 days prior to intake. And finally, the discrepancies in the percent
of patients reporting any illicit days of drug use suggest data collection errors may have
occurred and that retraining is necessary.
4.5.

Future work
Future research, once all spokes have been trained and initiated buprenorphine treatment,
can be conducted to determine whether the WV modified hub-and-spoke model was
effective in creating a statically significant increase in MAT capacity. According to the
SAMHSA buprenorphine treatment locator, there are currently 345 buprenorphine-waivered
prescribers at 225 unique sites in WV. Unlike publicly-funded substance abuse treatment
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programs, data on office-based buprenorphine treatment is not routinely collected and hence
the unique unduplicated number of patients treated is unknown. Previous research has found
that few prescribers treat the maximum number of patients (Walley et al., 2008) and
therefore it would important for future research to capture new prescribers and increased
capacity per existing prescribers. An implementation study is needed to further understand
barriers to buprenorphine treatment from both a provider and patient perspective, and
longer-term barriers to sustainability. The COAT leadership team is already engaged in work
to reduce stigma associated with MAT in the state, this includes addressing stigma in
educational training for both providers and community members, and working face-to-face
with key stakeholders.

5.

Conclusions

Author Manuscript

The STR-funded buprenorphine expansion in WV was successful in increasing
buprenorphine treatment capacity and the number of patients served. While this is only a
modest step in addressing the estimated 12,600 WV residents needing OUD treatment, it is
an essential step forward that has built the foundation for continued expansion and provided
a blueprint for ongoing clinical training for health professionals. WV’s modified hub-andspoke model may be a mechanism to expand buprenorphine/naloxone treatment in rural
areas, particularly in areas with transportation barriers and that lack geographic proximity to
opioid treatment programs. Interventions to reduce stigma and efforts to reduce regulatory
barriers are essential to the long-term success of the buprenorphine expansion.
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Fig. 1.

Map of hub and spokes.
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Fig. 2.

Organizational structure of the hub and spoke model.
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4

Frequent relapses

> 3 years

1–3 years

91–364 days

< 90 days
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Consecutive days AOD abstinence

Weekly mutual support groups
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35.0
97.4%
24.5%
30.0%
73.5%
63.2%
72.0%
7.5%
31.6%

Housed

More than HS/GED

Employed full or part time

Have children

Ever experienced serious depression

Ever experienced serious anxiety/
tension

Ever experienced trouble controlling
violent behav.

Prescribed psychiatric medication past
month

94.9%

White

Mean age

53.6%

Male

Overall

37.4%

6.1%

79.8%

71.7%

72.7%

29.3%

28.6%

95.9%

34.4

93.9%

53.5%

Morgantown Psychiatry
(n = 99)

21.4%

7.1%

52.5%

50.0%

71.8%

39.0%

16.7%

100.0%

37.0

95.2%

66.7%

Kanawha City
Primary care (n = 42)

28.6%

10.0%

58.8%

44.4%

65.0%

35.0%

19.1%

100.0%

31.9

95.2%

33.3%

Harpers Ferry
Primary care (n = 21)
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Baseline demographic & clinical characteristics (n = 196).

35.7%

14.3%

92.9%

71.4%

81.3%

11.8%

25.0%

100.0%

38.5

100.0%

47.1%

Charleston Psychiatry
(n = 17)

18.2%

9.1%

66.7%

54.6%

86.7%

23.1%

26.7%

93.3%

34.1

94.1%

52.9%

Huntington Psychiatry
(n = 17)
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Table 2

0.35

0.63

< 0.00

0.05

0.65

0.31

0.61

0.39

0.07

0.98

0.16

p value
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36.1%
15.8%
24.2%
47.4%

Injected drugs past 30 days

Any alcohol & illegal drug use past 30 days

Any Rx opioid use past 30 days

Any illicit buprenorphine use

64.2%

Any IV use in past 30 days
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Any injection drug use in past 30 days

Mean days of use past 30 days

Any use past 30 days

10.7%

5.6

15.8%

0

Any injection drug use in past 30 days

Cocaine/crack

7.3

Mean days of use past 30 days

Any use past 30 days

24.2%

14.4

Benzodiazepines

38.6%

Mean days of use past 30 days

41.3%

9.0

Any use past 30 days

Heroin

Any injection drug use in past 30 days

Mean days of use past 30 days

Any use past 30 days

45.5%

13.9

Mean days of use past 30 days

Methamphetamines

51.1%

Any use past 30 days

Marijuana

59.2%

3.9

8.0

20.4%

Any illegal drug use past 30 days

Mean days drinking ale. to intox. past mo.

Mean days alcohol use past 30 Days

Any alcohol use past 30 days

Overall

6.7%

6.3

15.2%

0

6.0

22.2%

54.6%

13.0

34.3%

47.6%

10.1

44.4%

12.1

49.0%

69.7%

19.2%

24.2%

31.1%

73.7%

3.8

6.3

28.3%

Morgantown Psychiatry
(n = 99)

0.0%

1.0

2.4%

0

5.9

26.2%

70.0%

15.3

47.6%

40.7%

9.0

64.3%

19.5

69.1%

45.2%

16.7%

7.1%

52.4%

33.3%

6.0

12.2

14.3%

Kanawha City
Primary care (n = 42)

25.0%

6.4

40.0%

0

2.0

5.0%

100.0%

23.1

35.0%

0.0%

1.0

4.8%

16.3

33.3%

4.8%

20.0%

0%

33.3%

57.1%

0

30

9.5%

Harpers Ferry
Primary care (n =
21)
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Baseline alcohol and drug use characteristics (n = 196).
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1.0
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0

13.6

43.8%

100.0%
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37.5%

25.0%

6.0

50.0%

5.7

43.8%

0.0%
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11.8%

21.4%

58.8%

2.0

2.0

11.8%

Charleston Psychiatry
(n = 17)

0.0%

2.0

30.8%

0

9.5

38.5%

50.0%

11.8

50.0%

16.7%

5.2

54.6%

7.6
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0.61

0.81

< 0.00

0.15

0.05

0.12

0.13

0.56

0.58

0.48

< 0.00

0.01

0.07
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0.01
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< 0.00

0.93

0.01
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p value
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16.7%

8.7

10.6%

20.0%

2.4

5.1%
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Huntington Psychiatry
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0.02
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